Zhejiang Dragon Technology (603004.SH) plans to invest 10 million yuan in the Anfengyuan Stone Fund.
Dinglong Technology (603004.SH) announced that in order to better promote the implementation of the company's development strategy and increase investment in new materials and other fields, leveraging the resource advantages and investment capabilities of specialized institutions to connect with richer industrial resources, the company intends to participate as a limited partner with its own funds of 10 million yuan in subscribing for shares of Hangzhou Anfeng Yuanshi Venture Capital Partnership (Limited Partnership) (referred to as Anfeng Yuanshi Fund) established by Anfeng Private Equity.
Zhejiang Dragon Technology (603004.SH) announced that in order to better promote the implementation of the company's development strategy and increase investment in new materials and other fields, leveraging the resource advantages and investment capabilities of professional institutions to connect richer industrial resources, the company plans to participate as a limited partner with its own funds of 10 million yuan to subscribe for shares in the Hangzhou Anfeng Yuanshi Venture Capital Partnership (Limited Partnership) established by Anfeng Private Equity (referred to as Anfeng Yuanshi Fund).
Related Articles

HK Stock Market Move | REFIRE (02570) plummeted over 20%, hitting a new low since its listing. It will officially be removed from the Hong Kong Stock Connect list starting today.

HK Stock Market Move | KINTOR PHARMA-B (09939) surged over 7% as the long-term safety trial of KT-939 has been successfully completed, and the company is actively advancing the related registration application work.

Sinolink: The second half of the year will see a dual benefit of new product launches and profit recovery in the PCB sector.
HK Stock Market Move | REFIRE (02570) plummeted over 20%, hitting a new low since its listing. It will officially be removed from the Hong Kong Stock Connect list starting today.

HK Stock Market Move | KINTOR PHARMA-B (09939) surged over 7% as the long-term safety trial of KT-939 has been successfully completed, and the company is actively advancing the related registration application work.

Sinolink: The second half of the year will see a dual benefit of new product launches and profit recovery in the PCB sector.

RECOMMEND





